The Joint Commission.jpg
The Joint Commission and the American College of Obstetricians and Gynecologists announce new collaboration to address maternal health
June 23, 2021 11:30 ET | Joint Commission
OAKBROOK TERRACE, Ill., June 23, 2021 (GLOBE NEWSWIRE) -- The Joint Commission and the American College of Obstetricians and Gynecologists (ACOG) today announced a new collaboration to help reduce...
ProgenityLogo.jpg
Sean Lavin, MD, Joins Progenity as Vice President, Business Development, Strategy, and Investor Relations
May 25, 2021 07:30 ET | Progenity, Inc.
SAN DIEGO, May 25, 2021 (GLOBE NEWSWIRE) -- Progenity, Inc. (Nasdaq: PROG), an innovative biotechnology company, today announced the appointment of Sean Lavin, M.D. as Vice President, Business...
ProgenityLogo.jpg
Progenity Provides Corporate Update and Reports First Quarter 2021 Financial Results
May 13, 2021 16:03 ET | Progenity, Inc.
Reports revenues of $24.5 million in the first quarter of 2021, up 72% from prior quarter Announced pre-validation data for its Preecludia™ test showed strong performance consistent with...
ProgenityLogo.jpg
Progenity Provides Key Update Regarding its Preecludia™ Test for Preeclampsia
May 05, 2021 07:30 ET | Progenity, Inc.
SAN DIEGO, May 05, 2021 (GLOBE NEWSWIRE) -- Progenity, Inc. (Nasdaq: PROG), a biotechnology company with an established track record of success in developing and commercializing molecular testing...
Obseva Logo4 (00000002).jpg
ObsEva SA presents posters at the ACOG Annual Clinical and Scientific Virtual Meeting April 30 - May 2, 2021
April 30, 2021 16:05 ET | ObsEva SA
GENEVA, Switzerland and BOSTON, MA – April 30, 2021 – ObsEva SA (NASDAQ: OBSV / SIX: OBSN) a biopharmaceutical company developing and commercializing novel therapies to improve women’s reproductive...
ProgenityLogo.jpg
Progenity Presents Key Verification Study Data for Preecludia™ Preeclampsia Rule-out Test at the 2021 American College of Obstetricians and Gynecologists (ACOG) Annual Meeting
April 30, 2021 16:04 ET | Progenity, Inc.
SAN DIEGO, April 30, 2021 (GLOBE NEWSWIRE) -- Progenity, Inc. (Nasdaq: PROG), a biotechnology company with an established track record of success in developing and commercializing molecular testing...
Agile_Logo-color on white.jpg
Agile Therapeutics Announces Presentation of Safety and Efficacy Data of Twirla® (Levonorgestrel and Ethinyl Estradiol) Transdermal System in Women of Differing BMI Categories at ACOG Annual Meeting
April 30, 2021 11:01 ET | Agile Therapeutics, Inc.
PRINCETON, N.J., April 30, 2021 (GLOBE NEWSWIRE) -- Agile Therapeutics, Inc. (Nasdaq: AGRX), a women's healthcare company, today announced that a post hoc analysis of the Phase 3 SECURE Trial...
ProgenityLogo.jpg
Progenity to Present Key Prospective Verification Study Data for its Preeclampsia Rule-Out Test at 2021 American College of Obstetricians and Gynecologists Annual Meeting
April 08, 2021 07:30 ET | Progenity, Inc.
SAN DIEGO, April 08, 2021 (GLOBE NEWSWIRE) -- Progenity, Inc. (Nasdaq: PROG), a biotechnology company with an established track record of success developing and commercializing molecular testing...
logo_new.jpg
ObsEva Announces Publication of Abstracts from Phase 2b EDELWEISS Trial of Linzagolix in Endometriosis
April 22, 2020 16:30 ET | ObsEva SA
   Significant improvement in quality of life outcomes maintained or increased after 52 weeks of treatment with linzagolixSmall, expected, non-clinically relevant increases in serum lipids...